文献速递神经肿瘤

如何处理巨大垂体腺瘤:经蝶窦还是经颅,同期还是分期?

How to deal with giant pituitary adenomas: transsphenoidal or transcranial, simultaneous or two-staged?
PubMed 文献 · J Neurooncol · 2017-01-11

回顾性分析2009至2015年62例巨大垂体腺瘤(直径>4 cm)患者的手术治疗,其中54例无功能腺瘤、8例激素分泌腺瘤,单经蝶窦入路43例(69.4%)、单经颅入路4例(6.5%)、联合经蝶窦与经颅入路13例(20.9%),另2例(3.2%)先行经颅手术后3个月再行经蝶窦入路。47例(75.8%)实现>90%切除,平均随访46.9个月,49例(79%)视力损害评分改善、无视力恶化,无术后出血或死亡,8例(12.9%)复发。

要点

  • 巨大垂体腺瘤(直径>4 cm)手术策略无共识,本组采用经蝶窦、经颅或联合入路个体化选择。
  • 47例(75.8%)达到>90%肿瘤切除,无术后出血及死亡,49例(79%)视力改善。
  • 作者认为可依据肿瘤特征灵活联合经蝶窦与经颅入路,特定病例同期联合可最大程度切除肿瘤并降低残余肿瘤肿胀出血风险。

核心结论

  • 对于巨大垂体腺瘤,应依据肿瘤特征灵活联合经蝶窦与经颅入路,特定病例同期联合入路可最大程度切除肿瘤并降低残余肿瘤肿胀和出血风险。

研究设计与样本

  • 回顾性分析2009至2015年在本院接受手术切除的62例成人巨大垂体腺瘤(直径>4 cm)患者,其中无功能腺瘤54例、激素分泌腺瘤8例。

主要发现

  • 单经蝶窦入路43例(69.4%),单经颅入路4例(6.5%),联合经蝶窦与经颅入路13例(20.9%),另2例(3.2%)先行经颅手术后3个月再行经蝶窦入路。
  • 47例(75.8%)实现>90%切除。
  • 平均随访46.9个月,49例(79%)视力损害评分改善,无视力恶化,无术后出血或死亡。
  • 27例(43.5%)接受辅助药物和/或放射治疗,末次随访时8例(12.9%)复发。

临床怎么用

  • 作者认为对于巨大垂体腺瘤,可依据肿瘤特征灵活联合经蝶窦与经颅入路;特定病例可采用同期联合入路以最大程度切除肿瘤并降低残余肿瘤肿胀和出血风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Giant pituitary adenomas (diameter >4 cm) are a challenge to treat, and there is no consensus on the optimal surgical strategy. We report here our experience in surgical management of these lesions. Adult patients with giant pituitary adenomas (n = 62; 54 non-functioning and eight hormone-secreting adenomas) who underwent surgical resection at our hospital from 2009 to 2015 were retrospectively reviewed. Surgical and clinical outcomes were analyzed. Single transsphenoidal and transcranial approaches were used in 43 (69.4%) and four (6.5%) patients, respectively. A combined transsphenoidal and transcranial approach was used in 13 patients (20.9%) and in two patients (3.2%), a transcranial procedure was followed 3 months later by a transsphenoidal approach. Greater than 90% resection was achieved in 47 cases (75.8%). During a mean follow-up period of 46.9 months, 49 patients (79%) showed improved visual impairment scores, while none experienced visual deterioration. There was no post-operative hemorrhage or mortality. A total of 27 patients (43.5%) received adjuvant medical and/or radiation therapy. At last follow-up, eight patients (12.9%) had recurrence. For giant pituitary adenoma, the transsphenoidal and transcranial approaches should be combined flexibly based on the characteristics of the tumor. In certain cases, a simultaneous combined approach can maximize tumor extirpation and lower the risk of swelling and bleeding of the residual tumor.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Han S, Gao W, Jing Z, et al. How to deal with giant pituitary adenomas: transsphenoidal or transcranial, simultaneous or two-staged? J Neurooncol. 2017. PMID: 28074324. doi:10.1007/s11060-017-2371-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。